Camp4 Therapeutics Past Earnings Performance
Past criteria checks 0/6
Camp4 Therapeutics's earnings have been declining at an average annual rate of -7.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-7.3%
Earnings growth rate
17.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -1,623.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Camp4 Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -52 | 13 | 2 |
| 30 Jun 24 | 0 | -50 | 12 | 2 |
| 31 Mar 24 | 0 | -50 | 12 | 2 |
| 31 Dec 23 | 0 | -49 | 12 | 2 |
Quality Earnings: CAMP is currently unprofitable.
Growing Profit Margin: CAMP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CAMP's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CAMP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAMP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CAMP has a negative Return on Equity (-1623.64%), as it is currently unprofitable.